Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience

International Journal of Urology

Volumn 9, Issue 6, 2002, Pages 340-346

  Azuma, Takeshi ^a   Horie, Shigeo ^a   Tomita, Kyoichi ^a   Takahashi, Tsuyoshi ^a   Tanaka, Yuji ^a   Kashiwase, Koichi ^b   Nieda, Mie ^b   Takeuchi, Takumi ^a   Ohta, Nobutaka ^a   Shibata, Yoichi ^a   Hirai, Hisamaru ^a   Kitamura, Tadaichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

Dendritic cell; Immunotherapy; Renal cell carcinoma

Indexed keywords

ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN;

ADULT; ARTICLE; CASE REPORT; CELL CULTURE; CELL LYSATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DISEASE COURSE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOTHERAPY; JAPAN; KIDNEY CARCINOMA; MALE; METASTASIS; MONOCYTE; PRIORITY JOURNAL; RADIODIAGNOSIS; TOXICITY; TUMOR; TUMOR VOLUME; VACCINATION; ACTIVE IMMUNIZATION; FOLLOW UP; IMMUNOLOGY; KIDNEY TUMOR; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOLOGY; TIME; UNIVERSITY HOSPITAL;

ADULT; CARCINOMA, RENAL CELL; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMAN; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS; MALE; MIDDLE AGE; OUTCOME ASSESSMENT (HEALTH CARE); TIME FACTORS; TOKYO; HUMANS; MIDDLE AGED;

EID: 0035996525     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2002.00477.x     Document Type: Article

References (21)

1. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone
2. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cell cancer: An outpatient multicenter trial
3. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place
4. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma
5. Tumor immunology
6. T cell defined tumor antigens
7. Dendritic cells as adjuvants for immune-mediated resistance to tumors
8. Cancer vaccines
9. Dendritic cells and the control of immunity
10. The dendritic cell system and its role in immunogenicity
11. Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
12. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell-associated cytokines
13. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
14. Origin, maturation and antigen presenting function of dendritic cells
15. Dendritic cells: Unique leukocyte populations which control the primary immune response
16. CD14+ blood monocytes can differentiate into functionary mature CD83+ dendritic cells
17. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
18. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
19. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
20. CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell carcinoma
21. Migration of human dendritic cells after injection in patients with metastatic malignancies